Novartis-GSK mega deal

European regulators have given conditional blessing to a proposed three-part deal between GlaxoSmithKline and Novartis, under which the firms will exchange assets and form a new consumer healthcare joint venture.

GSK intends to sell its portfolio of cancer drugs to Novartis for up to $16 billion and is buying the Swiss drug giant's vaccines unit for up to $7.1 billion (excluding flu jabs), and both plan to create "a world-leading consumer healthcare business" JV between Novartis OTC and GSK Consumer Healthcare. 

In relation to the vaccines acquisition, the European Commission has requested that GSK sell its meningitis vaccines, Nimenrix and Mencevax, on a global basis, and divest two small Novartis bivalent vaccines for protection against diphtheria and tetanus in Italy and Germany.

With regard to the consumer JV, GSK has agreed to sell its NiQuitin smoking cessation products and Coldrex cold & flu products in the European Economic Area, its local Panodil pain management and Nezeril/Nasin cold and flu products in Sweden, and Novartis’s topical cold sore business in the EEA.  

The deals remain subject to other closing conditions but bagging regulatory backing is a major advance, and the transaction is on track to complete during the first half of 2015, the firms noted.

Φαρμακευτικό Μάρκετινγκ: Θεωρία, Πρακτική, Δεοντολογία

The ultimate guide for Pharma Marketing Champions

Ζητήστε το στα κεντρικά βιβλιοπωλεία ή δώστε την παραγγελία σας τώρα…

http://www.stamoulis.gr/ViewShopProduct.aspx?ProductId=402023

Novartis expects 10 NME filings by end 2016

Novartis told investors today that it is entering a particularly fruitful period of product development, with 10 new molecular entities (NMEs) due to be submitted for approval in 2015 and 2016.

The hike in R&D output for the company's pharmaceuticals division comes after a transitional year for the company which saw it divest animal health and vaccines operations and set up a joint venture for over-the-counter drugs, allowing it to focus on its prescription medicine and eyecare businesses.

The new crop of filings - which includes potential blockbusters for cancer and heart failure - is coming through while Novartis is still enjoying buoyant growth for recently launched products, including oral multiple sclerosis therapy Gilenya (fingolimod), Jakavi (ruxolitinib) for myelofibrosis and its stable of therapies for chronic obstructive pulmonary disease (COPD).

How do doctors want to engage with pharma on new products?

With more than 80 per cent of European doctors saying they want to stay abreast of new developments about pharmaceutical products, it is important to understand how they wish to receive this information.

A survey by M3 Global Research of over 1,800 doctors from the top five EU countries and beyond has consolidated their thinking and finds that they value pharma's contribution. In fact, 72 per cent say the industry's delivery of new medicines will be the main factor helping to improve the outlook for their patients over the next three years.

Download the White Paper now to discover how doctors are accessing the latest developments about medicines and their preferred ways of receiving promotional material.

http://www.pharmaphorum.com/media/com_content/whitepaper/3146_how%20do%20doctors%20want%20to%20engage%20with%20pharma%20on%20new%20products11dec14.pdf

Φαρμακευτικό Μάρκετινγκ: Θεωρία, Πρακτική, Δεοντολογία

The ultimate guide for Pharma Marketing Champions

Ζητήστε το στα κεντρικά βιβλιοπωλεία ή δώστε την παραγγελία σας τώρα…

http://www.stamoulis.gr/ViewShopProduct.aspx?ProductId=402023

Drug Launch Watch List 2015 by Frost & Sullivan

Oncology, cardiovascular, autoimmune/anti-inflammatories, and infectious diseases will be the top areas of investments in 2015, according to Frost & Sullivan. Pharma companies will also be keen to invest in in-vitro diagnostics such as biomarkers; molecular, tissue, companion diagnostics; predisposition disease; and predictive testing, added the company's Life Sciences Global Program Director, Jennifer Lazar.

Frost & Sullivan has released its "Drug Launch and Phase 3 Trial Watch List for Top Therapy Areas for 2015". It includes: 

• Puma Biotechnology’s tyrosine kinase inhibitor, neratinib, for breast cancer adjuvant therapy.

• Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor, nivolumab, for previously treated advanced melanoma patients. 

• Novartis’ selective IL-17A inhibitor, secukinumab, for the treatment of plaque psoriasis. 

• Novartis’ angiotensin receptor neprilysin inhibitor (ARNi), LCZ696, for the treatment of heart failure.

• AbbVie’s ABT-450/ritonavir co-formulated with ombitasvir (ABT-267), and dasabuvir (ABT-333) with or without ribavirin for the treatment of hepatitis C.

• GlaxoSmithKline’s RTS,S vaccine is expected to be the first malaria vaccine in the market.

• Sanofi Pasteur's Dengue Vaccine. 

In addition to new molecular entity product launches, Frost & Sullivan reports that there are "abundant opportunities for generic and biosimilar drugs due to the patent expiry of several blockbuster drugs in 2014 and 2015". Some of those include: 

• Otsuka Pharmaceutical’s Abilify (anti-psychotic) 
• Teva Pharmaceutical’s Copaxone (relapse-remitting multiple sclerosis) 
• Novartis’ Gleevec (chronic myeloid leukemia) 
• Forest Laboratories’ Namenda (Alzheimer’s disease) 
• Pfizer’s Zyvox (anti-viral) and, 
• GlaxoSmithKline’s Avodart (benign prostatic hyperplasia) 

 

Φαρμακευτικό Μάρκετινγκ: Θεωρία, Πρακτική, Δεοντολογία

The ultimate guide for Pharma Marketing Champions

Ζητήστε το στα κεντρικά βιβλιοπωλεία ή δώστε την παραγγελία σας τώρα…

http://www.stamoulis.gr/ViewShopProduct.aspx?ProductId=402023

 

Top 7 Trends in Pharma Marketing for 2015

Source: PMLive

Here are the top 7 pharma marketing trends we expect big things from this year:

1. Patient Empowerment
2. Wearable Technology
3. Virtual Reality
4. Storytelling
5. Using biomarkers
6. Marketing and Medical Automation
7. Data, Security, and Privacy

They are by no means exhaustive and we will continue to share our views on what is having an impact and transforming the wider healthcare sector throughout the year.  Let us know whether you agree and your predictions for the year ahead. 

The 14 drugs most likely to top global pharma sales in 2015 and 2020

BioPharma Dive | By Sy Mukherjee

Earlier this week, BioPharma Dive reported on the 11 biggest expected drug launches to watch out for in 2015. BMS's anti-PD-1 drug Opdivo and PCSK9 cholesterol inhibitors from Sanofi and Amgen are expected to comprise some of the biggest launches in the industry and to eventually reach blockbuster status.
But there's plenty of already-approved drugs on the market right now that will likely make 2015 yet another massive year for pharma sales worldwide, according to equity analysts' projections aggregated in a big new report (gated) from EvaluatePharma. Old reliables like AbbVie's Humira and red-hot new hep C pills Sovaldi and Harvoni from Gilead Sciences are all expected to reach the upper tiers of marketing successes next year. But by 2020, several of the top 2010 products will probably fall off the list and be replaced with more recent potential blockbusters, so 14 drugs total are expected to rule the global pharma sales landscape over the next six years.
Here are the 10 meds projected to top global sales in 2015 (note: all images in this post are expandable; just click on a given chart if you have trouble reading the data):

The only recently-approved drugs that make the top 10 cut next year are Sovaldi and Harvoni. One important thing to keep in mind: Sovaldi/Harvoni sales are lumped together in this analysis, so technically, either of those two Gilead products alone would fall short of expected sales for AbbVie's anti-inflammatory Humira, the current top-selling drug in the world. But one interesting aspect of the EvalutePharma report is that it tracks how the top 2015 contenders will perform in 2020 (and vic versa).

Analysts expect M&A frenzy to continue with deals by Pfizer, AbbVie, Valeant likely in 2015

Pharma M&A in 2014 hit a record-breaking $234 billion in announced acquisitions. Actavis led the pack with its $66 billion bid for Botox maker Allergan and $25 billion buyout of Forest Laboratories. But investors and analysts say 2015 could generate as many or more deals, with Pfizer, Valeant Pharmaceuticals, AbbVie and Shire expected to be in the mix.

"2014 was clearly the year of the big deal," Rich Jeanneret, vice chair of EY's transaction advisory services, told Bloomberg. "I think that's going to persist in 2015 because there's much more confidence in the M&A ecosystem."

There also is cheap capital and the need to grow, and for the big boys, "the only real place they can find growth is through acquisition," Jeff Stute of JPMorgan Chase & Co. told the news service.

The 11 biggest drug launches to watch in 2015

BioPharma Dive | By Sy Mukherjee

This past year was a milestone one in the United States for new drugs, with novel therapeutics such as Gilead's pricey hep C cures Sovaldi and Harvoni coming to market (as well as a record 15 approvals for drugs to treat rare diseases), and huge sales of newer drugs like Roche's breast cancer med Kadcyla and Biogen Idec's MS blockbuster Tecfidera.

But according to a new report by EvaluatePharma (gated), 2015 could be equally impressive in terms of drug launches as innovative candidates in massive medical markets and exciting new drug classes in cancer immuno-therapy work their way towards approval. 

"The value of 2015 launches will be helped along by penetration into massive yet already well-trodden sectors like cardiovascular and respiratory disease, along with diabetes and schizophrenia," wrote the authors. "Drugs treating high cholesterol and heart failure are set to dominate the year's new products, with combine 2020 sales forecast at $8bn."